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February 2016 Abstracts S17mesenchymal markers, vimentin and N-cadherin in STM
cells. Enhanced invasion and migration capabilities were
observed in STM cells consistent with a mesenchymal
phenotype. Src has been shown to play a role in E-cadherin
regulation and EMT. Thus, treatment of cells with dasati-
nib, a Src inhibitor, suppressed cell growth in STM cells,
but not in ALKþ/TKI sensitive cell lines. The addition of a
low dose of dasatinib sensitized STM cells to the anti-
proliferative effects of crizotinib. STMcellswere subjected
to genetic analysis to identify new genetic anomalies that
could be driving resistance. Top hits are being evaluated.
To our knowledge, this is the ﬁrst report that demon-
strates EMT occurring in an ALKþ crizotinib resistant
clinical sample. Collectively these data support EMT as a
mechanism of resistance to crizotinib and identiﬁes
dasatinib as a potential therapeutic for treatment of cri-
zotinib resistance associated with EMT.
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Although PD-L1 immunohistochemical staining appears
to be a partially predictive biomarker of response to PD-1
inhibitors in some cancers, many PD-L1 positive tumors
do not respond to these agents. Possible explanations for
this observation are that some PD-L1 positive cancers
may have a paucity of inﬁltrating lymphocytes and/or T
cells within tumors may express multiple exhaustion
markers. We have developed a method for comprehen-
sive immune cell phenotyping using ﬂow cytometry on
solid tumors that have been dissociated into single cell
suspensions. Applying this technique to 33 resected ma-
lignant pleural mesothelioma samples, here we show that
compared to PD-L1 negative tumors, PD-L1 positive tu-
mors have signiﬁcantly more inﬁltrating CD45þ immune
cells, a signiﬁcantly higher proportion of inﬁltrating
CD3þ T cells, a signiﬁcant increase in proliferating CD4þ
and CD8þ T cells, and a signiﬁcantly higher percentage ofCD3þ cells displaying the activation antigens HLA-DRþ/
CD38þ. PD-L1 positive tumors also have a signiﬁcantly
higher proportion of FOXP3þ/CD4þ regulatory T cells.
We found that CD4þ and CD8þ T cells in PD-L1 positive
samples are signiﬁcantly more likely to express the T-cell
exhaustion markers PD-1 and TIM-3 compared to PD-L1
negative samples. Flow cytometric analysis also identi-
ﬁed two immunologically distinct PD-L1 positive meso-
thelioma samples: PD-1 positive, TIM-3 negative “single
positive” tumors, and PD-1 positive, TIM-3 positive
“double positive” tumors. Successful incorporation of
comprehensive immune proﬁling by ﬂow cytometry into
prospective clinical trials should hopefully reﬁne our
ability to predict which patients will respond to immune
checkpoint blockade and lead to rationally designed
combination immunotherapy trials.Novel epidermal growth factor
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Deaths from solid tumors are often not due to the pri-
mary lesion but to metastatic disease at distal sites such
as the lung, liver, and brain. Patients with non-small cell
lung cancer (NSCLC) experience brain metastases, a poor
prognostic marker, at an incidence rate of 30-50%. A
signiﬁcant proportion of the metastatic tumors express
activating mutations of the EGFR, including exon 19
deletions, which confer increased sensitivity to EGFR
inhibitors such as erlotinib and geﬁtinib. Despite suc-
cessful use of small molecule kinase inhibitors for the
treatment of EGFRþ primary lung tumors, current
therapeutics poorly inhibit the growth of NSCLC brain
metastases due to difﬁculty crossing the blood-brain
barrier. For this reason, NSCLC patients with brain me-
tastases are often excluded from clinical trials with novel
therapies and thus have access to very few emerging
treatment options.
We have synthesized a novel class of compounds that
inhibit the epidermal growth factor receptor (EGFR) in
the nanomolar range in vitro, and demonstrate a high
degree of selectivity for EGFR family members. The
parent compound, LL001, from Capella Therapeutics,
Inc., inhibited EGFR-mediated autophosphorylation and
S18 Journal of Thoracic Oncology Vol. 11 No. 2Sphosphorylation of downstream targets Akt and ERK
MAP kinase at a concentration of approximately 100nM
and blocked the kinase activity of an EGFR mutant,
T790M, which confers resistance to front-line EGFR in-
hibitors such as Tarceva. Compound LL001 induced full
remission of subcutaneous tumors using the human
NSCLC cell line H1975 (T790M/L858Rþ). Most notably,
pharmacokinetic studies showed that LL001, when
administered at a concentration of 150mg/kg in mice,
showed no signs of toxicity and accumulated in the brain
at concentrations ranging from 12-171 times higher than
the GI50 for inhibition of EGFRþ NSCLC cell line prolif-
eration in vitro.
In order to determine whether LL001 could effec-
tively treat NSCLC brain metastases, we developed an
intracranial injection orthotopic xenograft model for
the study of NSCLC brain lesions. We found that LL001
could induce complete remission of brain tumors in
67% of mice injected with the human NSCLC cell line
HCC827-luciferase, which expresses an exon 19 dele-
tion mutant of EGFR. Compound LL001 (75mg/kg/day)
reduced tumor burden in the brain to undetectable
levels by in vitro imaging (IVIS) and performed signif-
icantly better than Tarceva, a reference compound. We
conclude that compound LL001 crosses the blood brain
barrier at levels sufﬁcient to block the growth of
EGFRþ NSCLC brain metastases and therefore may be
therapeutically useful for a critically underserved pa-
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Non-small cell lung cancer (NSCLC) is a subtype of lung
cancer that is the leading cause of cancer-related mor-
tality. The average 5-year relative survival rate for
NSCLC patients is estimated to be 15.7% depending on
the stage of diagnosis. 224,210 new cases of lung can-
cer, and 159,260 deaths were reported in the year
2014. Out of these reported numbers, NSCLC makes up
almost 80% of cases. More importantly the patients are
often found in late stages due to ineffective diagnosis
and relative insensitivity to chemotherapy. NSCLC is a
complex disease due to presence of large number of
genomic alterations, such as EGFR overexpression that
has been reported to be overexpressed anywhere from
43-89% depending on factors such as stage, ethnicity,and diagnostic method used. EGFR-expressing lung
cancers are treated with anti-EGFR drugs such as
monoclonal antibodies or small molecule tyrosine ki-
nase inhibitors. Upon treatment with tyrosine kinase
inhibitors (TKIs), NSCLC tumors have shown to acquire
resistance to TKIs through mutations that circumvent
the EGFR pathways targeted. One marker that has been
shown to arise in tumors treated with anti-EGFR ther-
apies is the c-Met (HGF) receptor. Once a patient has
undergone several months of EGFR targeted therapy,
often times a subsequent biopsy will show that the
tumor now expresses a large amount of c-Met protein
instead of the previously diagnosed EGFR expression.
We will thus explore the notion that for a substantial
amount of EGFR-expressing NSCLC tissues, there will be
a population of cells which overexpress the c-Met re-
ceptor at the stage of initial diagnosis which are
allowed to continue growth since EGFR is the only
therapeutic target utilized for the patient treatment. As
a result, a better recommendation for patient treatment
would include therapies targeted both at c-Met and
EGFR. For this study, we have acquired NSCLC tissues
from patients who have been treated with anti-EGFR
therapy. To assess levels of EGFR and c-Met in the tis-
sues, we use our platform IHC nanotechnology con-
sisting of gold nanorods (GNR) targeted to either
receptor by means of surface modiﬁcation. By adding a
modiﬁed peptide speciﬁc for EGFR or c-Met to the
surface of the gold nanorod, we assess levels of both
EGFR and c-Met in the tissues through imaging. GNR
stained tissue images can be analyzed quantitatively
through speciﬁc image processing algorithms, allowing
for a precise, accurate method of diagnosis compared to
conventional IHC. Tissue levels of c-Met present and the
patient response to anti-EGFR treatment will then be
compared to determine if the patient would likely
beneﬁt from initial treatment targeted at both c-Met
and EGFR.
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Lung cancer remains the leading cause of cancer
mortality in United States and globally. Pemetrexed
